Clinical trials: Oral Anticoagulant
Oligohydramnios
Warfarine in Unexplained Oligohydramnios
This study examines using oral anti coagulant warfarin in the management of unexplained oligohydramnios improve the perinatal outcome with little or no complications to the mother or the neonates.
- Trial name
- NCT01569035
- Testing
- warfarin
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Woman's Health University Hospital, Egypt
Anticoagulant-induced Bleeding, Periodontal Diseases
Evaluation of the Intra- and Post- Operative Bleeding After Periodontal Debridement in Direct Anticoagulant Patients
Direct Oral Anticoagulants were recently approved for medical treatment of several condition such as, non valvular atrial fibrillation, deep venous thrombosis, and others, substituting sometimes the conventional oral…
- Trial name
- NOADB_db (NCT03124004)
- Testing
- periodontal debridement
- Where
- Italy
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Trieste
Direct Oral Anticoagulants (DOACs), Oral Surgical Procedures
Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
Direct oral anticoagulants (DOACs) are increasingly used, but evidence on bleeding risk during oral soft tissue biopsy is limited.
- Trial name
- DOACS_BX (NCT07520890)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Oral Anticoagulant Therapy
Dental Implants in Patients Under Oral Anticoagulant Therapy
This study evaluated the outcomes in the post-operative recovery following dental implant surgery in patients who continued on oral anticoagulated therapy (OAT) with warfarin.
- Trial name
- NCT04846114
- Testing
- Dental implant surgery
- Where
- Argentina
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Jorge Ernesto Aguilar
Anticoagulants, Platelet Aggregation Inhibitors
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
The study will assess the hypothesis that the combination warfarin \& clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally…
- Conditions
- Anticoagulants, Platelet Aggregation Inhibitors, Stents, Atrial Fibrillation
- Trial name
- WOEST (NCT00769938)
- Testing
- PCI (percutaneous coronary intervention)
- Where
- 15 sites in Belgium, Netherlands
- Volunteers
- 573 people, healthy volunteers welcome
- Sponsor
- R&D Cardiologie
Healthy
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
This study aims to evaluate the effects of combination therapy of tegoprazan and novel oral anticoagulants (NOACs) on the pharmacokinetic and pharmacodynamic properties of NOACs in healthy adults.
- Trial name
- NCT05723510
- Testing
- Tegoprazan 50mg, Edoxaban 60mg, Apixaban 5mg
- Where
- South Korea
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Deep Vein Thrombosis, Pulmonary Embolism
Impact of Pharmacists' Training on Oral Anticoagulant Counseling
This study evaluates the impact of community pharmacists' educational training on the nature and adequacy of counseling provided to patients on warfarin, an oral anticoagulant.
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT03999905
- Testing
- Counseling training
- Where
- Nigeria
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Ibadan
Novel Oral Anticoagulants, NOACs
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants
It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT03161496
- Testing
- detection of genotype
- Where
- 17 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Cui Yimin
Anticoagulant-induced Bleeding, Dental Diseases
Intra- and Post- Operative Bleeding After Simple Dental Extraction in Direct Oral Anticoagulant Therapy
Direct Oral Anticoagulants were recently approved for medical treatment of several condition such as, non valvular atrial fibrillation, deep venous thrombosis, and others, substituting sometimes the conventional oral…
- Trial name
- NOADB (NCT03124030)
- Testing
- simple dental extraction
- Where
- Italy
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Trieste
Healthy Volunteers
A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability and Pharmacokinetics/Pharmacodynamics of multiple doses of GCC-4401C in healthy male subjects.
- Trial name
- NCT01954238
- Testing
- GCC-4401C, Rivaroxaban
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Anticoagulants, Self Efficacy
Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy
This study aims to develop and validate an index measurement tool to assess the patient's self-care self-efficacy in managing oral anticoagulation therapy (OAC).
- Conditions
- Anticoagulants, Self Efficacy, Self Confidence
- Trial name
- SCSE-OAC (NCT05820854)
- Testing
- Self-assess and reporting self-care self-efficacy levels
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- IRCCS Policlinico S. Donato
Deep Vein Thrombosis, Superficial Thrombophlebitis
DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients
Study using a decision algorithm for the application of an oral anticoagulant calculator in vascular diseases, aimed at validating a clinical decision-support tool for conditions such as deep vein thrombosis, superficial…
- Conditions
- Deep Vein Thrombosis, Superficial Thrombophlebitis, Pulmonary Thromboembolisms, Clinical Decision Support Systems
- Trial name
- DOACT (NCT07290608)
- Testing
- DOACT algorithm, No algorithm, LLM-based tools
- Where
- Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- ITALO EUGENIO SOUZA GADELHA DE ABREU
Atrial Fibrillation (AF), Ischemic Stroke
Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy
Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.
- Trial name
- SAFER-DOAC (NCT07713537)
- Testing
- DOAC Level
- Where
- 2 sites in Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Anticoagulant Drugs, Diabetes Mellitus, Type 2
Effect of an Electronic Reminder System on Direct Oral Anticoagulant and Oral Diabetes Medication Adherence
In this study, the effect of an electronic device attached to a push through pill package and a smart phone application on chronic disease medication adherence is studied.
- Trial name
- NCT03753568
- Testing
- Electronic medicine reminder system
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Atrial Fibrillation, Stroke
A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF
This is a prospective, single-arm, feasibility pilot study of 20 participants (aged 60 years or older, with additional stroke risk factors and 'actionable' undertreated AF) recruited from a total of 4 retail and outpatient…
- Trial name
- APOTHECARYAF (NCT04907825)
- Testing
- Oral anticoagulant
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Drug-Related Side Effects and Adverse Reactions, Treatment Failure
DOAC ADRs Retrospective Study on Genetic Variations
The purpose of this study is to see if the participant's genetic profile and clinical factors (age, drug dose, etc.) affect drug outcomes (i.e.
- Trial name
- DARES1 (NCT04580589)
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Cipherome, Inc.
Thrombosis, Anticoagulant-induced Bleeding
Reversal of the Antithrombotic Action of New Oral Anticoagulants
The main goal of this study is to improve safety and efficiency of clinical practice with the new generation of oral anticoagulants. 1.
- Conditions
- Thrombosis, Anticoagulant-induced Bleeding, Anticoagulant Overdosage, Hemorrhage
- Trial name
- REVANT (NCT01478282)
- Testing
- Rivaroxaban, Dabigatran
- Where
- Spain
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Gines Escolar
Anticoagulant Disorders
Management of Direct Oral Anti-Coagulants (DOACs) for Gastrointestinal Endoscopy Procedures
The use of Direct Oral Anti-Coagulants (DOACs) is expanding, but their proper management in patients undergoing endoscopic procedures is still not completely clear. Current European guidelines are based on weak data.
- Trial name
- NCT02734316
- Testing
- endoscopic procedure
- Where
- Italy
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- Valduce Hospital
Coagulation Disorder
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
A single centre, open-label study to assess the effects of VMX-C001 in combination with an oral FXa DOAC on the efficacy of Unfractionated Heparin (UFH) and of VMX-C001 alone on the efficacy of Low Molecular Weight Heparin (LMWH)…
- Trial name
- NCT06517563
- Testing
- VMX-C001, Rivaroxaban, UFH
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.